Literature DB >> 28673739

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.

Jacqueline A Gleave1, Lindsay R Arathoon1, Dennison Trinh1, Kristin E Lizal1, Nicolas Giguère2, James H M Barber1, Zainab Najarali1, M Hassan Khan1, Sherri L Thiele1, Mahin S Semmen1, James B Koprich3, Jonathan M Brotchie3, James H Eubanks3, Louis-Eric Trudeau2, Joanne E Nash4.   

Abstract

Parkinson's disease (PD) is a neurodegenerative movement disorder, which affects approximately 1-2% of the population over 60years of age. Current treatments for PD are symptomatic, and the pathology of the disease continues to progresses over time until palliative care is required. Mitochondria are key players in the pathology of PD. Genetic and post mortem studies have shown a large number of mitochondrial abnormalities in the substantia nigra pars compacta (SNc) of the parkinsonian brain. Furthermore, physiologically, mitochondria of nigral neurons are constantly under unusually high levels of metabolic stress because of the excitatory properties and architecture of these neurons. The protein deacetylase, Sirtuin 3 (SIRT3) reduces the impact subcellular stresses on mitochondria, by stabilising the electron transport chain (ETC), and reducing oxidative stress. We hypothesised that viral overexpression of myc-tagged SIRT3 (SIRT3-myc) would slow the progression of PD pathology, by enhancing the functional capacity of mitochondria. For this study, SIRT3-myc was administered both before and after viral induction of parkinsonism with the AAV-expressing mutant (A53T) α-synuclein. SIRT3-myc corrected behavioural abnormalities, as well as changes in striatal dopamine turnover. SIRT3-myc also prevented degeneration of dopaminergic neurons in the SNc. These effects were apparent, even when SIRT3-myc was transduced after the induction of parkinsonism, at a time point when cell stress and behavioural abnormalities are already observed. Furthermore, in an isolated mitochondria nigral homogenate prepared from parkinsonian SIRT3-myc infected animals, SIRT3 targeted the mitochondria, to reduce protein acetylation levels. Our results demonstrate that transduction of SIRT3 has the potential to be an effective disease-modifying strategy for patients with PD. This study also provides potential mechanisms for the protective effects of SIRT3-myc. Crown
Copyright © 2017. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mitochondria; Neuroprotection; Parkinson's disease; Sirtuin 3; Substantia nigra; Virally over-expressing mutant α-synuclein rat

Mesh:

Substances:

Year:  2017        PMID: 28673739     DOI: 10.1016/j.nbd.2017.06.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  12 in total

Review 1.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Authors:  Yvette C Wong; Kelvin Luk; Kerry Purtell; Samuel Burke Nanni; A Jon Stoessl; Louis-Eric Trudeau; Zhenyu Yue; Dimitri Krainc; Wolfgang Oertel; Jose A Obeso; Laura A Volpicelli-Daley
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

Review 2.  Reciprocal Interactions of Mitochondria and the Neuroimmunoendocrine System in Neurodegenerative Disorders: An Important Role for Melatonin Regulation.

Authors:  Victoria O Polyakova; Igor M Kvetnoy; George Anderson; Jessica Rosati; Gianluigi Mazzoccoli; Natalya S Linkova
Journal:  Front Physiol       Date:  2018-03-12       Impact factor: 4.566

3.  The Role of SIRT3 in the Brain Under Physiological and Pathological Conditions.

Authors:  Elena Sidorova-Darmos; Rosa Sommer; James H Eubanks
Journal:  Front Cell Neurosci       Date:  2018-07-25       Impact factor: 5.505

4.  Mitochondrial Respiration in Intact Peripheral Blood Mononuclear Cells and Sirtuin 3 Activity in Patients with Movement Disorders.

Authors:  Slawomir Michalak; Jolanta Florczak-Wyspiańska; Joanna Rybacka-Mossakowska; Wojciech Ambrosius; Krystyna Osztynowicz; Aleksandra Baszczuk; Wojciech Kozubski; Ewa Wysocka
Journal:  Oxid Med Cell Longev       Date:  2017-09-10       Impact factor: 6.543

Review 5.  On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease.

Authors:  Nicolas Giguère; Samuel Burke Nanni; Louis-Eric Trudeau
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

6.  Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway.

Authors:  Jae-Hyeon Park; Jeremy D Burgess; Ayman H Faroqi; Natasha N DeMeo; Fabienne C Fiesel; Wolfdieter Springer; Marion Delenclos; Pamela J McLean
Journal:  Mol Neurodegener       Date:  2020-01-13       Impact factor: 14.195

7.  Microbubble drug conjugate and focused ultrasound blood brain barrier delivery of AAV-2 SIRT-3.

Authors:  Dennison Trinh; Joanne Nash; David Goertz; Kullervo Hynynen; Sharsi Bulner; Umar Iqbal; James Keenan
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

8.  A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.

Authors:  Martin Timo Henrich; Fanni Fruzsina Geibl; Bolam Lee; Wei-Hua Chiu; James Benjamin Koprich; Jonathan Michael Brotchie; Lars Timmermann; Niels Decher; Lina Anita Matschke; Wolfgang Hermann Oertel
Journal:  Acta Neuropathol Commun       Date:  2018-05-10       Impact factor: 7.801

9.  SIRT3 Regulation of Mitochondrial Quality Control in Neurodegenerative Diseases.

Authors:  Hao Meng; Wan-Yu Yan; Yu-Hong Lei; Zheng Wan; Ye-Ye Hou; Lian-Kun Sun; Jue-Pu Zhou
Journal:  Front Aging Neurosci       Date:  2019-11-12       Impact factor: 5.750

Review 10.  Imbalance of Lysine Acetylation Contributes to the Pathogenesis of Parkinson's Disease.

Authors:  Rui Wang; Hongyang Sun; Guanghui Wang; Haigang Ren
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.